2 completed, 2 unknown, 1 terminated. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Unknown 2, Terminated 1 |
| Phase 2 | 2 | Terminated 1, Unknown 1 |
Follow SHR2554: new trials by email Literature Review of SHR2554 trials Research Report on SHR2554
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects SHR2554 - Malignant Tumor | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 20 | 2022-11-15 | 2022-12-19 |
| A Umbrella Study in R/R PTCL Guided by Molecular Subtypes Azacitidine Injection, Dasatinib, Linperlisib - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Ruijin Hospital | 116 | 2022-09-30 | 2022-11-09 |
| A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects SHR2554 - Healthy Adult Subjects | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 20 | 2019-08-06 | 2020-04-06 |
| A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC SHR3680, SHR2554 - Prostate Cancer, Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 9 | 2018-11-20 | 2021-02-05 |
| A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms SHR2554 - Relapsed or Refractory Mature Lymphoid Neoplasms | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 272 | 2018-08-14 | 2024-10-01 |
Lymphoma, T-Cell, Peripheral (1) · Neoplasms (1) · Prostatic Neoplasms (1) · Recurrence (1)
Jiangsu HengRui Medicine Co., Ltd. (4) · Ruijin Hospital (1)
China (5)
Dingwei Ye, M.D. (1) · Weili Zhao (1)